WO2001049309A3 - Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue - Google Patents

Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue Download PDF

Info

Publication number
WO2001049309A3
WO2001049309A3 PCT/IB2000/001935 IB0001935W WO0149309A3 WO 2001049309 A3 WO2001049309 A3 WO 2001049309A3 IB 0001935 W IB0001935 W IB 0001935W WO 0149309 A3 WO0149309 A3 WO 0149309A3
Authority
WO
WIPO (PCT)
Prior art keywords
damaged tissue
treatment
upa
mmp
combinations
Prior art date
Application number
PCT/IB2000/001935
Other languages
French (fr)
Other versions
WO2001049309A2 (en
Inventor
Michael John Davies
Jonathan Paul Huggins
Fraser Stuart Mcintosh
Nicholas Laurence Occleston
Original Assignee
Pfizer Ltd
Pfizer
Michael John Davies
Jonathan Paul Huggins
Fraser Stuart Mcintosh
Nicholas Laurence Occleston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Pfizer, Michael John Davies, Jonathan Paul Huggins, Fraser Stuart Mcintosh, Nicholas Laurence Occleston filed Critical Pfizer Ltd
Priority to AU18782/01A priority Critical patent/AU1878201A/en
Priority to JP2001549676A priority patent/JP2003519193A/en
Priority to CA002395487A priority patent/CA2395487A1/en
Priority to EP00981550A priority patent/EP1242120A2/en
Publication of WO2001049309A2 publication Critical patent/WO2001049309A2/en
Publication of WO2001049309A3 publication Critical patent/WO2001049309A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
PCT/IB2000/001935 1999-12-29 2000-12-21 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue WO2001049309A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU18782/01A AU1878201A (en) 1999-12-29 2000-12-21 Composition for the treatment of damaged tissue
JP2001549676A JP2003519193A (en) 1999-12-29 2000-12-21 Composition for the treatment of damaged tissue
CA002395487A CA2395487A1 (en) 1999-12-29 2000-12-21 Composition for the treatment of damaged tissue
EP00981550A EP1242120A2 (en) 1999-12-29 2000-12-21 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9930768.8 1999-12-29
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (2)

Publication Number Publication Date
WO2001049309A2 WO2001049309A2 (en) 2001-07-12
WO2001049309A3 true WO2001049309A3 (en) 2002-02-28

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001935 WO2001049309A2 (en) 1999-12-29 2000-12-21 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue

Country Status (12)

Country Link
EP (1) EP1242120A2 (en)
JP (1) JP2003519193A (en)
AR (1) AR027122A1 (en)
AU (1) AU1878201A (en)
CA (1) CA2395487A1 (en)
CO (1) CO5271671A1 (en)
EC (1) ECSP003859A (en)
GB (1) GB9930768D0 (en)
GT (1) GT200000224A (en)
PE (1) PE20011095A1 (en)
UY (1) UY26514A1 (en)
WO (1) WO2001049309A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE456655T1 (en) 2000-10-16 2010-02-15 Genentech Inc TREATMENT METHODS USING WISP POLYPEPTIDES
WO2003013569A2 (en) * 2001-07-27 2003-02-20 The Board Of Regents, The University Of Texas System Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
WO2003029819A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Method of screening preventive/remedy for bone/joint diseases
WO2004014937A2 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
WO2005065706A1 (en) 2003-12-31 2005-07-21 Orthologic Corp. Pharmaceutical composition for thrombin peptide derivatives
JP5361386B2 (en) * 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Matrix metalloproteinase 11 vaccine
KR20150072458A (en) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
KR101629504B1 (en) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 Composition for improving skin conditions containing a combination of cytokines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (en) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd Novel composition for external use
WO1995024921A1 (en) * 1994-03-16 1995-09-21 Institute Of Ophthalmology A medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (en) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd Novel composition for external use
WO1995024921A1 (en) * 1994-03-16 1995-09-21 Institute Of Ophthalmology A medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 124, no. 16, 15 April 1996, Columbus, Ohio, US; abstract no. 211858, LEE, YOO-CHEOL ET AL: "Formulation of water-soluble topical preparations of epidermal growth factor" XP002183324 *
DATABASE WPI Section Ch Week 198951, Derwent World Patents Index; Class B04, AN 1989-374113, XP002183325 *
KIYOHARA, YOSHIFUMI ET AL: "Cytoprotective effects of epidermal growth factor ( EGF ) ointmen containing nafamostat, a protease inhibitor, on tissu damage at burn sites in rats", BIOL. PHARM. BULL. (1993), 16(11), 1146-9, XP001034376 *
KIYOHARA, YOSHIFUMI ET AL: "Improvement in wound healing by epidermal growth factor ( EGF ) ointment: efficacy of EGF ointment containing protease inhibitor, nafamostat, for ischemic ulcer (decubitus) in rats", YAKUZAIGAKU (1994), 54(2), 117-21, XP001034399 *
KIYOHARA, YOSHIFUMI ET AL: "Systemic effects of epidermal growth factor ( EGF ) ointment containing protease inhibitor or gelatin in rats with burns or open wounds. Part III", BIOL. PHARM. BULL. (1993), 16(1), 73-6, XP001039589 *
TARNUZZER, ROY W. ET AL: "Epidermal growth factor in wound healing: a model for the molecular pathogenesis of chronic wounds", GROWTH FACTORS WOUND HEALING, [PROC. INT. SYMP.] (1997), MEETING DATE 1995, 206-228. EDITOR(S): ZIEGLER, THOMAS R.;PIERCE, GLENN F.; HERNDON, DAVID N. PUBLISHER: SPRINGER, NEW YORK, N. Y., XP001035111 *
YAKCHE HAKHOECHI (1995), 25(3), 177-84 *

Also Published As

Publication number Publication date
AU1878201A (en) 2001-07-16
PE20011095A1 (en) 2001-10-27
UY26514A1 (en) 2001-07-31
AR027122A1 (en) 2003-03-12
GB9930768D0 (en) 2000-02-16
WO2001049309A2 (en) 2001-07-12
ECSP003859A (en) 2002-09-27
EP1242120A2 (en) 2002-09-25
CA2395487A1 (en) 2001-07-12
JP2003519193A (en) 2003-06-17
GT200000224A (en) 2002-06-15
CO5271671A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
AU2746595A (en) Metalloproteinase inhibitors
MY133996A (en) Compounds for the treatment of ischemia
EP1210941A3 (en) Pharmaceutical compositions containing ritonavir (ABT-538) in combination with indinavir (MK-639) and their use for treating AIDS
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU3511500A (en) Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2001049309A3 (en) Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue
EP1162956B8 (en) Compositions and methods for improving integrity of compromised body passageways and cavities
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
MY126962A (en) A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
AU644621B2 (en) Pharmaceutical composition for treating or preventing retroviral infections
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
AU2001252278A1 (en) Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance
CA2262582A1 (en) Hcg and derivatives as matrix metalloproteases inhibitors
HUP0402645A2 (en) Pharmaceutical composition comprising a glitazone and 4-oxobutanoic acid, and the use thereof for treating diabetes
ATE329613T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING GROWTH HORMONES INHIBITORS OR THEIR BIOLOGICALLY ACTIVE FRAGMENTS FOR THE TREATMENT OF UTERINE MYOMAS
WO2002100342A3 (en) (s, s'), (s, r')-amphetaminil, compositions and uses thereof
WO2002100346A3 (en) (r, r'),(r',s')-amphetaminil, compositions and uses thereof
UA32302A (en) Method for preventing postoperative deformities of soft tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000981550

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2395487

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 549676

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000981550

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000981550

Country of ref document: EP